Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.

[1]  Sung-Bae Kim,et al.  Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC) , 2009, Breast Cancer Research and Treatment.

[2]  S. Ko.  Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996–2006) using nationwide breast cancer registration on‐line program: Biannual update , 2008, Journal of surgical oncology.

[3]  T. Delea,et al.  Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective , 2008, Breast Cancer Research and Treatment.

[4]  W. Han,et al.  Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Bennett,et al.  Early discontinuation of tamoxifen , 2007, Cancer.

[6]  T. Powles,et al.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. , 2007, Journal of the National Cancer Institute.

[7]  H. Johansson,et al.  Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen , 2007, Breast Cancer Research and Treatment.

[8]  Sang Min Park,et al.  Trends in breast cancer treatment in Korea and impact of compliance with consensus recommendations on survival , 2007, Breast Cancer Research and Treatment.

[9]  M. Rossing,et al.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.

[10]  K. Yoo,et al.  Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996–2004 , 2006, Breast Cancer Research and Treatment.

[11]  P. Bult,et al.  Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[13]  W. Gerth,et al.  Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  Hai-rim Shin,et al.  2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. , 2004, Cancer research and treatment : official journal of Korean Cancer Association.

[15]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[16]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[17]  J. Robertson,et al.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Gradishar,et al.  The cost effectiveness of tamoxifen in the prevention of breast cancer. , 1999, The American journal of managed care.

[19]  C. Park.  The National Assembly of the Republic of Korea , 1998 .

[20]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[21]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[22]  V. Jordan.  Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen. , 1990, Journal of the National Cancer Institute.

[23]  Anthony J. Culyer,et al.  The NICE Cost-Effectiveness Threshold , 2012, PharmacoEconomics.

[24]  Lisa Dolovich,et al.  Patient Adherence to Osteoporosis Medications , 2007, Drugs & aging.

[25]  Dong-Young Noh,et al.  Long-term prediction of female breast cancer mortality in Korea. , 2005, Asian Pacific journal of cancer prevention : APJCP.

[26]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[27]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.